On ⁢December 10, ⁢2025, a single-judge bench of an Indian ⁢court extended a previous ruling regarding‍ Dr. Reddy’s Laboratories to Sun Pharmaceutical‍ Industries, permitting‌ the⁢ company to manufacture and export semaglutide -​ a drug used to ‍treat type 2 diabetes and obesity – ​to countries without patent ‍protection. However, the court maintained a restriction on domestic sales of the generic version within India.

This decision followed a separate lawsuit filed by Novo Nordisk, the original patent holder of⁣ semaglutide (marketed as Ozempic and Wegovy), seeking to prevent Sun Pharma from⁤ launching its generic version of the drug in anticipation of a potential early market⁢ entry. Novo Nordisk currently imports semaglutide into India, but does not manufacture it locally, while Dr. Reddy’s operations where previously limited to exports.

Background: The Semaglutide Patent Landscape

Semaglutide has become a highly sought-after medication due to ⁢its effectiveness in managing type 2 diabetes and, increasingly, for weight loss. Novo Nordisk holds patents on the ⁢drug,wich grant them exclusive rights to manufacture and ‍sell it for a specified period. However, ​generic drug manufacturers like Dr. Reddy’s and Sun​ Pharma often challenge these patents,‌ seeking to ‍introduce more affordable alternatives once the patent⁣ expires or through legal arguments regarding patent ‍validity.

The legal ‌battles ‍surrounding ‍semaglutide reflect a broader trend in the pharmaceutical‍ industry, where ‍companies fiercely defend their intellectual ‌property while generic manufacturers push for wider access to essential medicines. India, known as the “pharmacy of the world,” ⁤plays a crucial⁤ role in ‌this dynamic, as it is indeed a major producer of generic ⁣drugs.

The Dr. Reddy’s Case ​and its Implications

The court’s decision to extend the reasoning from the Dr. Reddy’s case to Sun Pharma suggests a willingness⁤ to allow Indian companies to contribute to the global supply of affordable semaglutide,especially for countries where patent protection is not enforced. the initial ruling in the Dr. Reddy’s case established conditions under which generic manufacturing and export were permitted, likely ⁤focusing on non-infringement of Novo Nordisk’s patents in specific export markets.

The restriction on domestic sales is likely ⁣intended to protect Novo​ Nordisk’s market share within India, ⁣where its patents remain valid.​ This creates a situation where Indian manufacturers can serve as suppliers to ⁣the global market, but not directly compete with novo Nordisk within their home ​country.

Novo Nordisk’s Response and‍ Future Outlook

Novo Nordisk’s proactive legal action demonstrates‍ its⁢ commitment to protecting its intellectual property and maintaining its⁤ dominance in the semaglutide market. the company may continue to pursue legal challenges to prevent generic competition, both in India and in other jurisdictions.

The outcome of⁤ these legal battles will have important implications for ⁢the availability and affordability of semaglutide worldwide. increased generic competition could lower prices and improve ‍access for patients, while continued patent protection would allow Novo​ Nordisk to maintain higher prices and ​recoup its investment in research⁤ and advancement.